Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 1, 2009, Pages 223-228

  Louie, T ^a,f   Miller, M ^b   Donskey, C ^c   Mullane, K ^d   Goldstein, E J C ^e  

^a UNIVERSITY OF CALGARY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e R M ALDEN RESEARCH LABORATORY   (United States)

^f FOOTHILLS HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; METRONIDAZOLE; TIACUMICIN B; VANCOMYCIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG FECES LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKOCYTE COUNT; MALE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLYCOSIDES; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 59749084849     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01442-07     Document Type: Article

References (31)

1. Al-Nassir, W. N., A. K. Sethi, M. M. Nerandzic, G. S. Bobulsky, R. L. Jump, and C. J. Donskey. 2008. Comparison of clinical and microbiological response to treatment of Clostridium difficile disease with metronidazole and vancomycin. Clin. Infect. Dis. 47:56-62.
2. Bartlett, J. G. 1992. Antibiotic-associated diarrhea. Clin. Infect. Dis. 15:573-581.
3. Bartlett, J. G. 2006. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann. Intern. Med. 145:758-764.
4. Belmares, J., D. N. Gerding, J. P. Parada, S. Miskevics, F. Weaver, and S. Johnson. 2007. Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J. Infect. 55:495-501.
5. Bouza, E., A. Burillo, and P. Munoz. 2006. Antimicrobial therapy of Clostridium difficile-associated diarrhea. Med. Clin. N. Am. 90:1141-1163.
6. Credito, K. L., and P. C. Appelbaum. 2004. Activity of OPT-80, a novel macrocycle compared with those of eight other agents against selected anaerobic species. Antimicrob. Agents Chemother. 48:4430-4434.
7. Fekety, R., and A. B. Shah. 1993. Diagnosis and treatment of Clostridium difficile colitis. JAMA 269:71-75.
8. Finegold, S. M., D. Molitoris, M. L. Vaisanen, Y. Song, C. Liu, and M. Bolaños. 2004. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob. Agents Chemother. 48:4898-4902.
9. Guerrant, R. L., J. M. Hughes, N. L. Lima, and J. Crane. 1990. Diarrhea in developed and developing countries: magnitude, special settings, and etiologies. Rev. Infect. Dis. 12(Suppl. 1):S41-S50.
10. Hauck, W., and S. Anderson. 1986. A comparison of large sample confidence interval methods for the difference of two binomial probabilities. Am. Statistician 40:318-322.
11. Hecht, D. W., M. A. Galang, S. P. Sambol, J. R. Osmolski, S. Johnson, and D. N. Gerding. 2007. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob. Agents Chemother. 51:2716-2719.
12. Hochlowski, J. E., S. J. Swanson, L. M. Ranfranz, D. N. Whittern, A. M. Buko, and J. B. McAlpine. 1987. Tiacumicins, a novel complex of 18-membered macrolides. II. Isolation and structure determination. J. Antibiot. (Tokyo) 40:575-588.
13. Hogenauer, C., H. F. Hammer, G. J. Krejs, and E. C. Reisinger. 1998. Mechanisms and management of antibiotic-associated diarrhea. Clin. Infect. Dis. 27:702-710.
14. Kelly, C. P., C. Pothoulakis, and J. T. LaMont. 1994. Clostridium difficile colitis. N. Engl. J. Med. 330:257-262.
15. Kuijper, E. J., B. Coignard, and B. Tull; the ESCMID Study Group for Clostridium difficile (ESGCD). 2006. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin. Microbiol. Infect. 12(Suppl. 6):2-18.
16. Loo, V. G., L. Poirier, M. A. Miller, M. Oughton, M. D. Libman, S. Michaud, A.-M. Bourgault, T. Nguyen, C. Frenette, M. Kelly, A. Vibien, P. Brassard, S. Fenn, K. Dewar, T. J. Hudson, R. Horn, P. Rene, Y. Monczak, and A. Dascal. 2005. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353:2442-2449.
17. Louie, T., M. Miller, C. Donskey, K. Mullane, E. J. C. Goldstein, M. Corrado, C. F. Okumu, S. Gorbach, P. Sears, S. Shangle, B. Walsh, Y. K. Shue, and R. A. Preston. 2005. Safety, pharmacokinetics and outcomes of PAR-1 in healthy subjects and patients with Clostridium difficile-associated diarrhea (CDAD), abstr. LB2-29, p. 226. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
18. Louie, T. J., M. Miller, C. Donskey, K. Mullane, E. J. C. Goldstein, D. M. Citron, M. Corrado, S. L. Gorbach, P. Sears, S. Shangle, B. Walsh, and Y.-K. Shue. 2006. A clinical and laboratory evaluation of PAR-101 in patients with Clostridium difficile-associated diarrhoea. Clin. Microbiol. Infect. 12(Suppl. 4):39.
19. McDonald, L. C., G. E. Killgore, A. Thompson, R. C. Owens, Jr., S. V. Kazakova, S. V. Sambol, S. Johnson, and D. N. Gerding. 2005. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353:2433-2441.
20. McFarland, L. V. 1995. Epidemiology of infectious and iatrogenic nosocomial diarrhea in a cohort of general medicine patients. Am. J. Infect. Control 23:295-305.
21. Miller, M. A., M. Hyland, M. Ofner-Agostini, M. Gourdeau, and M. Ishak. 2002. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect. Control Hosp. Epidemiol. 23:137-140.
22. Musher, D. M., S. Aslam, N. Logan, S. Nallacheru, I. Bhaila, F. Borchert, and R. J. Hamill. 2005. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin. Infect. Dis. 40:1586-1590.
23. Pepin, J., M. E. Alary, L. Valiquette, E. Raiche, J. Ruel, K. Fulop, D. Godin, and C. Bourassa. 2005. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin. Infect. Dis. 40:1591-1597.
24. Pepin, J., L. Valiquette, M. E. Alary, P. Villemure, A. Pelletier, K. Forget, K. Pepin, and D. Chouinard. 2004. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171:466-472.
25. Shue, Y. K., P. S. Sears, S. Shangle, R. B. Walsh, C. Lee, S. L. Gorbach, F. Okumu, and R. A. Preston. 2008. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob. Agents Chemother. 52:1391-1395.
26. Swanson, R. N., D. J. Hardy, N. L. Shipkowitz, C. W. Hanson, N. C. Ramer, P. B. Fernandes, and J. J. Clement. 1991. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrob. Agents Chemother. 35:1108-1111.
27. Theriault, R. R., J. P. Karwowski, M. Jackson, R. L. Girolami, G. N. Sunga, C. M. Vojtko, and L. J. Coen. 1987. Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation and antibacterial activity. J. Antibiot. (Tokyo) 40:567-574.
28. Wilcox, M. H., and R. Howe. 1995. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J. Antimicrob. Chemother. 36:673-679.
29. Wistrom, J., S. R. Norrby, E. B. Myhre, S. Eriksson, G. Granstrom, L. Lagergren, G. Englund, C. E. Nord, and B. Svenungsson. 2001. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J. Antimicrob. Chemother. 47:43-50.
30. Yamamoto-Osaki, T., S. Kamiya, S. Sawamura, M. Kai, and A. Ozawa. 1994. Growth inhibition of Clostridium difficile by intestinal flora of infant feces in continuous flow culture. J. Med. Microbiol. 40:179-187.
31. Zar, F. A., S. R. Bakkanagari, K. M. L. S. T. Moorthi, and M. B. Davis. 2007. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45:302-307.